Minireview: Nanoparticles and the Immune System

Zolnik, Banu S.; González-Fernández, África; Sadrieh, Nakissa; Dobrovolskaia, Marina A.

doi:10.1210/en.2009-1082

Cited by 782 publications

(528 citation statements)

References 67 publications

Supporting

Mentioning

511

Contrasting

Order By: Relevance

“…Upon IP delivery, nanoparticles are directly administered at the target site. Hence, interactions of the nanoparticles with blood components that potentially induce immune responses or stability issues could be avoided [48]. The stability of nanoparticles in the IP fluid is a major determinant for their efficacy.…”

Section: Discussionmentioning

confidence: 99%

Colloidal stability of nano-sized particles in the peritoneal fluid: Towards optimizing drug delivery systems for intraperitoneal therapy

et al. 2014

View full text Add to dashboard Cite

Intraperitoneal (IP) administration of nano-sized delivery vehicles containing small interfering RNA (siRNA) is recently gaining attention as an alternative route for the efficient treatment of peritoneal carcinomatosis. The colloidal stability of nanomatter following IP administration has, however, not been thoroughly investigated yet. Here, enabled by advanced microscopy methods such as Single Particle Tracking (SPT) and Fluorescence Correlation Spectroscopy (FCS), we follow the aggregation and cargo release of nano-scaled systems directly in peritoneal fluids from healthy mice and ascites fluid from a patient diagnosed with peritoneal carcinomatosis. The colloidal stability in the peritoneal fluids was systematically studied in function of the charge (positive or negative) and Poly-Ethylene Glycol (PEG) degree of liposomes and polystyrene nanoparticles, and compared to human serum. Our data demonstrate strong aggregation of cationic and anionic nanoparticles in the peritoneal fluids, while only slight aggregation was observed for the PEGylated ones. PEGylated liposomes, however, lead to a fast and premature release of siRNA cargo in the peritoneal fluids. Based on our observations, we reflect on how to tailor improved delivery systems for IP therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Colloidal stability of nano-sized particles in the peritoneal fluid: Towards optimizing drug delivery systems for intraperitoneal therapy

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The physical characteristics of nanoparticles, such as size, surface charge, hydrophobicity/hydrophilicity and the steric effects of their coatings, can dictate the compatibility between the nanoparticles and the immune system. 2 Silver nanoparticles (AgNPs) are among the most commercialized nanoparticles because of their unique optical, catalytic and disinfectant properties. Currently, AgNPs are being used for many different applications, [3][4][5] ranging from wound dressing and the coatings of surgical instruments and prostheses 6,7 to the use in food container systems or as the coating material for certain household devices, such as washing machines.…”

Section: Introductionmentioning

confidence: 99%

Immunomodulatory properties of silver nanoparticles contribute to anticancer strategy for murine fibrosarcoma

et al. 2015

View full text Add to dashboard Cite

The use of nanotechnology in nanoparticle-based cancer therapeutics is gaining impetus due to the unique biophysical properties of nanoparticles at the quantum level. Silver nanoparticles (AgNPs) have been reported as one type of potent therapeutic nanoparticles. The present study is aimed to determine the effect of AgNPs in arresting the growth of a murine fibrosarcoma by a reductive mechanism. Initially, a bioavailability study showed that mouse serum albumin (MSA)-coated AgNPs have enhanced uptake; therefore, toxicity studies of AgNP-MSA at 10 different doses (1-10 mg/kg b.w.) were performed in LACA mice by measuring the complete blood count, lipid profile and histological parameters. The complete blood count, lipid profile and histological parameter results showed that the doses from 2 to 8 mg (IC 50 : 6.15 mg/kg b.w.) sequentially increased the count of leukocytes, lymphocytes and granulocytes, whereas the 9-and 10-mg doses showed conclusive toxicity. In an antitumor study, the incidence and size of fibrosarcoma were reduced or delayed when murine fibrosarcoma groups were treated by AgNP-MSA. Transmission electron micrographs showed that considerable uptake of AgNP-MSA by the sentinel immune cells associated with tumor tissue and a morphologically buckled structure of the immune cells containing AgNP-MSA. Because the toxicity studies revealed a relationship between AgNPs and immune function, the protumorigenic cytokines TNF-a, IL-6 and IL-1b were also assayed in AgNP-MSA-treated and non-treated fibrosarcoma groups, and these cytokines were found to be downregulated after treatment with AgNP-MSA. Cellular & Molecular Immunology

show abstract

“…This enhances the contribution of off-target effects and makes the choice of targeting moiety critical. Even if a highly specific targeting moiety is used, the effectiveness of nanoparticles that display these targeting moieties is often limited by their immune clearance (15,16). The ability of particles to avoid immune clearance and accumulate at the target depends on several parameters, including size, shape, surface chemistry, and flexibility (17)(18)(19)(20)(21)(22).…”

mentioning

confidence: 99%

Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium

Kolhar

Anselmo²,

Gupta³

et al. 2013

Proc. Natl. Acad. Sci. U.S.A.

575

507

View full text Add to dashboard Cite

Vascular endothelium offers a variety of therapeutic targets for the treatment of cancer, cardiovascular diseases, inflammation, and oxidative stress. Significant research has been focused on developing agents to target the endothelium in diseased tissues. This includes identification of antibodies against adhesion molecules and neovascular expression markers or peptides discovered using phage display. Such targeting molecules also have been used to deliver nanoparticles to the endothelium of the diseased tissue. Here we report, based on in vitro and in vivo studies, that the specificity of endothelial targeting can be enhanced further by engineering the shape of ligand-displaying nanoparticles. In vitro studies performed using microfluidic systems that mimic the vasculature (synthetic microvascular networks) showed that rodshaped nanoparticles exhibit higher specific and lower nonspecific accumulation under flow at the target compared with their spherical counterparts. Mathematical modeling of particle-surface interactions suggests that the higher avidity and specificity of nanorods originate from the balance of polyvalent interactions that favor adhesion and entropic losses as well as shear-induced detachment that reduce binding. In vivo experiments in mice confirmed that shape-induced enhancement of vascular targeting is also observed under physiological conditions in lungs and brain for nanoparticles displaying anti-intracellular adhesion molecule 1 and anti-transferrin receptor antibodies.biodistribution | morphology | SMN | cylinder | drug delivery

show abstract

Minireview: Nanoparticles and the Immune System

Cited by 782 publications

References 67 publications

Colloidal stability of nano-sized particles in the peritoneal fluid: Towards optimizing drug delivery systems for intraperitoneal therapy

Colloidal stability of nano-sized particles in the peritoneal fluid: Towards optimizing drug delivery systems for intraperitoneal therapy

Immunomodulatory properties of silver nanoparticles contribute to anticancer strategy for murine fibrosarcoma

Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium

Contact Info

Product

Resources

About